Biotech
Syndeio Biosciences
Syndeio Biosciences raises $90M Series at $450M valuation
$90M
Total Raised
Series
Latest Round
2022
Founded
60+
Employees
Indianapolis, IN
1 min read
Quick Facts
Valuation
$450M
Latest Round Size
$90M
Latest Round Date
May 2024
Syndeio Biosciences: Series Funding Round
Syndeio Biosciences has successfully raised $90M in Series funding, reaching a valuation of $450M.
Company Overview
Developer of precision neurotherapeutics for CNS diseases
Funding Details
The Series round was led by Eli Lilly and Company, with participation from ARCH Venture Partners.
Company Information
- Headquarters: Indianapolis, IN
- Founded: 2022
- Employees: 60+
- Category: Biotech
Investment
Syndeio Biosciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Eli Lilly and Company: Verified investor in Series
- ARCH Venture Partners: Verified investor in Series
Key Investors
Eli Lilly and Company
Lead Investor
Verified investor in Series
ARCH Venture Partners
Investor
Verified investor in Series
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M